Medtronic won the European Union CE Mark for its Micra AV pacemaker that’s delivered into the heart, where it resides without requiring any leads, using a minimally invasive transcatheter procedure.
The device is indicated for patients suffering from AV block, a condition that prevents proper electrical signal transfer between the atria and the ventricle. Micra AV addresses this condition by continuously monitoring the physical movement of the heart, using a built-in accelerometer, and adjusting how it paces the ventricle at every heartbeat.
“This new device not only stimulates but is also able to recognize the electrical activity of the whole heart. Our ultimate goal is to bring the latest cardiovascular innovation to patients in our area. Now we can extend this wireless technology to other patients who require dual-chamber stimulation and in whom traditional stimulation cannot be performed or is conditioned by previous infections, occlusions of the vessels of the upper extremities, etc.,” said Dr. José Ramón González Juanatey, director of the Cardiology and Intensive Cardiac Care Department at University Hospital, Santiago de Compostela, Spain, in a Medtronic press release.
Some relevant clinical trial data, according to the company:
The Micra AV approval is based on data from the MARVEL 2 (Micra Atrial Tracking Using A Ventricular accELerometer) study, which evaluated the safety and effectiveness of accelerometer-based atrial sensing algorithms. The study evaluated the ability of the Micra’s internal sensor to monitor and detect atrial contractions and enable coordinated pacing between the atrium and ventricle, thereby providing AV synchrony. Results from the study, presented at the American Heart Association 2019 Scientific Sessions and published simultaneously in JACC: Clinical Electrophysiology, showed the primary efficacy objective was met, with a significantly greater percentage of complete heart block patients with normal sinus rhythm having >70% AV synchrony during algorithm-mediated AV synchronous pacing (38 of 40 patients, 95%) than VVI pacing (0 patients, P<0.001 for proportion of patients with >70% synchrony). The study’s primary safety objective was also met, with no pauses or episodes of pacing-induced tachycardia reported during algorithm mediated AV synchronous pacing.
Product page:Micra AV
Flashbacks: Medtronic’s Tiny New Micra AV Pacemaker for AV Block FDA Approved; World’s Smallest Endocardial Pacemaker Getting Implanted in Initial Set of Patients; Medtronic’s Tiny Micra Pacemaker Going on a Space Flight; Medtronic’s Micra Pacemaker Survives Flight to Space; Medtronic’s Tiny Micra Leadless Pacemaker Approved in U.S.; Medtronic Introduces Micra, World’s Smallest Pacemaker; Medtronic Micra, World’s Smallest Pacemaker That Lives Inside Heart, Cleared in Europe
more recommended stories
First Dedicated Pediatric and Neonatal Acute Dialysis Machine Released U.S.
Medtronic is releasing in the United.
ivWatch Monitors IV Placement Sites for Leakage, Now Cleared by FDA
ivWatch, a company based in Newport.
Nanoparticles for Large Gene Therapy to Cure Common Eye Diseases
Wet age-related macular degeneration and a.
Micro-LEDs and Solar Panels Wirelessly Power Medical Implants
Researchers at the Gwangju Institute of.
Revolutionizing IV Access With TournIQ: Interview With Jonathan Ilicki, Co-Founder of Ortrud Medical
IV access is one of the.
Robotic Transcranial Doppler for Stroke Detection and Risk Assessment in COVID: Interview with Diane Bryant, Neural Analytics
Emerging evidence suggests that COVID-19 patients.
The Impact of COVID-19 on The Medical Device Industry
As of early May 2020, over.
A Virtual Care Platform for Respiratory Illness: Interview with Stacie Ruth, CEO of AireHealth
AireHealth, a medtech company based in.
Noona Cloud Tool for Cancer Patients: Interview with Jani Ahonala, VP, Global Patient Outcomes, Varian Medical
Varian Medical Systems, based in Palo.
Sweat Sensor Gathers Large Samples for Accurate Analysis
Sweat excreted by the skin contains.